View in EDS HTML Full Text PDF Full Text

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

Saved in:
Bibliographic Details
Title: First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Authors: Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Xu B; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Rodon JA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Raghav K; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mott F; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fan Y; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Fan J; Clinical Department, TransThera Sciences (US), Inc., Gaithersburg, MA, USA., Peng P; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Wang H; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Ni S; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Sun C; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Qiang X; Biology Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Levin WJ; Clinical Department, CRC Oncology, San Diego, CA, USA., Ngo B; Clinical Department, CRC Oncology, San Diego, CA, USA., Ru QC; Clinical Department, CRC Oncology, San Diego, CA, USA., Wu F; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Javle MM; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Source: The oncologist [Oncologist] 2024 Apr 04; Vol. 29 (4), pp. e514-e525.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38297981
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Xu+B%22">Xu B</searchLink>; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Dumbrava+EE%22">Dumbrava EE</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Karp+DD%22">Karp DD</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Rodon+JA%22">Rodon JA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Raghav+K%22">Raghav K</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ajani+JA%22">Ajani JA</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Conley+AP%22">Conley AP</searchLink>; Department of Sarcoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Mott+F%22">Mott F</searchLink>; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fan+Y%22">Fan Y</searchLink>; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Fan+J%22">Fan J</searchLink>; Clinical Department, TransThera Sciences (US), Inc., Gaithersburg, MA, USA.<br /><searchLink fieldCode="AU" term="%22Peng+P%22">Peng P</searchLink>; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Ni+S%22">Ni S</searchLink>; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Sun+C%22">Sun C</searchLink>; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Qiang+X%22">Qiang X</searchLink>; Biology Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Levin+WJ%22">Levin WJ</searchLink>; Clinical Department, CRC Oncology, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ngo+B%22">Ngo B</searchLink>; Clinical Department, CRC Oncology, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ru+QC%22">Ru QC</searchLink>; Clinical Department, CRC Oncology, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wu+F%22">Wu F</searchLink>; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Javle+MM%22">Javle MM</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2024 Apr 04; Vol. 29 (4), pp. e514-e525.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38297981
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyad338
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e514
    Titles:
      – TitleFull: First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Xu B
      – PersonEntity:
          Name:
            NameFull: Dumbrava EE
      – PersonEntity:
          Name:
            NameFull: Fu S
      – PersonEntity:
          Name:
            NameFull: Karp DD
      – PersonEntity:
          Name:
            NameFull: Meric-Bernstam F
      – PersonEntity:
          Name:
            NameFull: Hong DS
      – PersonEntity:
          Name:
            NameFull: Rodon JA
      – PersonEntity:
          Name:
            NameFull: Tsimberidou AM
      – PersonEntity:
          Name:
            NameFull: Raghav K
      – PersonEntity:
          Name:
            NameFull: Ajani JA
      – PersonEntity:
          Name:
            NameFull: Conley AP
      – PersonEntity:
          Name:
            NameFull: Mott F
      – PersonEntity:
          Name:
            NameFull: Fan Y
      – PersonEntity:
          Name:
            NameFull: Fan J
      – PersonEntity:
          Name:
            NameFull: Peng P
      – PersonEntity:
          Name:
            NameFull: Wang H
      – PersonEntity:
          Name:
            NameFull: Ni S
      – PersonEntity:
          Name:
            NameFull: Sun C
      – PersonEntity:
          Name:
            NameFull: Qiang X
      – PersonEntity:
          Name:
            NameFull: Levin WJ
      – PersonEntity:
          Name:
            NameFull: Ngo B
      – PersonEntity:
          Name:
            NameFull: Ru QC
      – PersonEntity:
          Name:
            NameFull: Wu F
      – PersonEntity:
          Name:
            NameFull: Javle MM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 04
              Text: 2024 Apr 04
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1